KCG
NBIX icon

Knight Capital Group’s Neurocrine Biosciences NBIX Stock Holding History

Knight Capital Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$223K Buy
+16,671
New +$205K ﹤0.01% 2591

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Knight Capital Group's NBIX Position: Q2 2013 in Review

Knight Capital Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2013: 16,671 shares worth $223K. The stake represents ﹤0.01% of the portfolio and ranks #2591 among its holdings.

126 funds tracked by Wall St. Rank hold NBIX as of Q2 2013.

  • Knight Capital Group held 16,671 shares of Neurocrine Biosciences worth $223K as of Q2 2013.
  • Neurocrine Biosciences was a new Knight Capital Group position in Q2 2013.
  • Neurocrine Biosciences made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #2591 holding.
  • 126 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.